189 related articles for article (PubMed ID: 38551047)
21. Molecular insights and novel approaches for targeting tumor metastasis.
Das SS; Alkahtani S; Bharadwaj P; Ansari MT; ALKahtani MDF; Pang Z; Hasnain MS; Nayak AK; Aminabhavi TM
Int J Pharm; 2020 Jul; 585():119556. PubMed ID: 32574684
[TBL] [Abstract][Full Text] [Related]
22. Targeted Drug Therapy to Overcome Chemoresistance in Triple-negative Breast Cancer.
Kumari M; Krishnamurthy PT; Sola P
Curr Cancer Drug Targets; 2020; 20(8):559-572. PubMed ID: 32370716
[TBL] [Abstract][Full Text] [Related]
23. The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.
Huynh NT; Roger E; Lautram N; Benoît JP; Passirani C
Nanomedicine (Lond); 2010 Nov; 5(9):1415-33. PubMed ID: 21128723
[TBL] [Abstract][Full Text] [Related]
24. Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy.
González-Fernández Y; Imbuluzqueta E; Patiño-García A; Blanco-Prieto MJ
Curr Pharm Des; 2015; 21(42):6104-24. PubMed ID: 26503148
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer.
He Y; Huang Y; Huang Z; Jiang Y; Sun X; Shen Y; Chu W; Zhao C
J Control Release; 2017 Oct; 264():76-88. PubMed ID: 28842315
[TBL] [Abstract][Full Text] [Related]
26. Cytosolic co-delivery of miRNA-34a and docetaxel with core-shell nanocarriers via caveolae-mediated pathway for the treatment of metastatic breast cancer.
Zhang L; Yang X; Lv Y; Xin X; Qin C; Han X; Yang L; He W; Yin L
Sci Rep; 2017 Apr; 7():46186. PubMed ID: 28383524
[TBL] [Abstract][Full Text] [Related]
27. Targeted drug delivery systems for matrix metalloproteinase-responsive anoparticles in tumor cells: A review.
Guo F; Du Y; Wang Y; Wang M; Wang L; Yu N; Luo S; Wu F; Yang G
Int J Biol Macromol; 2024 Feb; 257(Pt 1):128658. PubMed ID: 38065446
[TBL] [Abstract][Full Text] [Related]
28. The development of site-specific drug delivery nanocarriers based on receptor mediation.
Wang X; Li S; Shi Y; Chuan X; Li J; Zhong T; Zhang H; Dai W; He B; Zhang Q
J Control Release; 2014 Nov; 193():139-53. PubMed ID: 24862317
[TBL] [Abstract][Full Text] [Related]
29. Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis.
She X; Chen L; Yi Z; Li C; He C; Feng C; Wang T; Shigdar S; Duan W; Kong L
Mini Rev Med Chem; 2018; 18(11):976-989. PubMed ID: 27145854
[TBL] [Abstract][Full Text] [Related]
30. Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges.
Yu X; Zhu L
Int J Nanomedicine; 2024; 19():1867-1886. PubMed ID: 38414525
[TBL] [Abstract][Full Text] [Related]
31. Polymeric nanoparticles for cancer therapy.
Parveen S; Sahoo SK
J Drug Target; 2008 Feb; 16(2):108-23. PubMed ID: 18274932
[TBL] [Abstract][Full Text] [Related]
32. Calcium-bisphosphonate Nanoparticle Platform as a Prolonged Nanodrug and Bone-Targeted Delivery System for Bone Diseases and Cancers.
Lin Y; Villacanas MG; Zou H; Liu H; Carcedo IG; Wu Y; Sun B; Wu X; Prasadam I; Monteiro MJ; Li L; Xu ZP; Gu W
ACS Appl Bio Mater; 2021 Mar; 4(3):2490-2501. PubMed ID: 35014367
[TBL] [Abstract][Full Text] [Related]
33. Application of nanoparticles in drug delivery for the treatment of osteosarcoma: focussing on the liposomes.
Liang W; Dong Y; Shao R; Zhang S; Wu X; Huang X; Sun B; Zeng B; Zhao J
J Drug Target; 2022 Jun; 30(5):463-475. PubMed ID: 34962448
[TBL] [Abstract][Full Text] [Related]
34. Nanocarriers for anticancer drugs--new trends in nanomedicine.
Drbohlavova J; Chomoucka J; Adam V; Ryvolova M; Eckschlager T; Hubalek J; Kizek R
Curr Drug Metab; 2013 Jun; 14(5):547-64. PubMed ID: 23687925
[TBL] [Abstract][Full Text] [Related]
35. Dendronized Systems for the Delivery of Chemotherapeutics.
Dockery L; Daniel MC
Adv Cancer Res; 2018; 139():85-120. PubMed ID: 29941108
[TBL] [Abstract][Full Text] [Related]
36. Breast Cancer Targeted Treatment Strategies: Promising Nanocarrier Approaches.
Malliappan SP; Kandasamy P; Chidambaram S; Venkatasubbu D; Perumal SK; Sugumaran A
Anticancer Agents Med Chem; 2020; 20(11):1300-1310. PubMed ID: 31642415
[TBL] [Abstract][Full Text] [Related]
37. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
[TBL] [Abstract][Full Text] [Related]
38. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
Zhang W; Liu M; Liu A; Zhai G
Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy.
Wickens JM; Alsaab HO; Kesharwani P; Bhise K; Amin MCIM; Tekade RK; Gupta U; Iyer AK
Drug Discov Today; 2017 Apr; 22(4):665-680. PubMed ID: 28017836
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonate-functionalized micelles for targeted delivery of curcumin to metastatic bone cancer.
Kamble S; Varamini P; Müllner M; Pelras T; Rohanizadeh R
Pharm Dev Technol; 2020 Nov; 25(9):1118-1126. PubMed ID: 32686553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
